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Abstract
Background & Aims: Radiological progression patterns to first-line sorafenib have 
been associated with post-progression and overall survival in advanced hepatocel-
lular carcinoma, but these associations remain unknown for therapies in second- and 
later-line settings. This post hoc analysis of REACH and REACH-2 examined out-
comes by radiological progression patterns in the second-line setting of patients with 
advanced hepatocellular carcinoma treated with ramucirumab or placebo.
Methods: Patients with advanced hepatocellular carcinoma, Child-Pugh A and 
Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib 
were randomized to receive ramucirumab 8mg/kg or placebo every 2 weeks. Among 
625 patients with ≥1 progression pattern (new extrahepatic lesion [including new 
macrovascular invasion], new intrahepatic lesion, extrahepatic growth or intrahe-
patic growth), data were analysed by trial and for pooled individual patient data for 
REACH-2 and REACH (alpha-fetoprotein ≥400 ng/mL). Cox models evaluated prog-
nostic implications of progression patterns on overall and post-progression survival.
Results: Post-progression survival was worse among those with new extrahepatic 
lesions in REACH (HR 2.33, 95% CI 1.51-3.60), REACH-2 (HR 1.49, 95% CI 0.72-3.08) 
and the pooled population (HR 1.75, 95% CI 1.12-2.74) compared to other progres-
sion patterns. Overall survival was also significantly reduced in those with new ex-
trahepatic lesions across studies. Ramucirumab provided an overall survival benefit 
across progression patterns, including patients with new extrahepatic lesions (HR 
0.56, 95% CI 0.39-0.80) in the pooled population.
Conclusions: The emergence of new extrahepatic lesions in the second-line setting 
is a poor prognostic factor for post-progression survival. The benefit of ramucirumab 
for overall survival was consistent across progression patterns.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1  | INTRODUC TION
Vascular endothelial growth factor (VEGF) is overexpressed in hepa-
tocellular carcinoma (HCC), and thus VEGF receptors (VEGFRs) 1 and 
2 and their ligands play an important role in tumour angiogenesis and 
contribute to the pathogenesis and progression of advanced HCC.1 
Several antiangiogenic multikinase inhibitors targeting this pathway 
have demonstrated clinical benefits in the phase 3 setting, including 
sorafenib and lenvatinib in the first-line, regorafenib for sorafenib-tol-
erant patients, and cabozantinib in patients intolerant or refractory to 
sorafenib.2-4 Ramucirumab (an immunoglobulin G1 VEGFR-2 antago-
nist) is the first and only treatment approved in a biomarker-selected 
population with alpha-fetoprotein (AFP) concentrations ≥400 ng/mL in 
advanced HCC.5,6 Global approvals were based on evidence from the 
phase 3 REACH and REACH-2 studies in which ramucirumab, compared 
to placebo, demonstrated superior overall survival (OS) in patients with 
baseline AFP) concentrations ≥400 ng/mL following sorafenib.4,7,8
Among patients with advanced HCC, radiological progression pat-
terns, specifically the presence of new extrahepatic lesions and/or vas-
cular invasion on first-line sorafenib, have been associated with poorer 
OS and post-progression survival (PPS) compared to other radiological 
progression patterns.3,9-11 Pattern of progression on first-line sorafenib 
was prognostic of poorer survival in other trials of second-line rego-
rafenib12 and tivantinib cohorts.13 However, these second-line studies 
were limited in that progression patterns were examined only in first-
line sorafenib and not during second-line treatment.
The response evaluation criteria in solid tumours (RECIST) ver-
sion 1.1,14 and modified RECIST (mRECIST)15 are commonly used to 
evaluate time to tumour progression in HCC trials. However, neither 
RECIST nor mRECIST use progression patterns in evaluating tumour 
progression, which could refine the characterization of both, as sug-
gested by the prognostic value in the first-line sorafenib setting.9-13 
Determining the utility of radiological progression patterns as a 
stratification or prognostic factor is critical for improving the design 
and analysis of second-line and later advanced HCC trials.9,11,12
The objective of this study was to examine the incidence of radiolog-
ical progression patterns in the second-line advanced HCC setting and to 
determine whether there is a relationship between progression pattern 
and OS and PPS in patients treated with ramucirumab or placebo.
2  | PATIENTS AND METHODS
2.1 | Study design
Phase 3 REACH and REACH-2 study designs have been previously 
reported in detail (Figure S1).7,8 Briefly, 565 patients (n = 283 in the 
ramucirumab arm and n = 282 in the placebo arm) were enrolled 
in the randomized, placebo-controlled, double-blind REACH trial, 
250 of whom had AFP concentrations ≥400 ng/mL. In REACH-2, 
a randomized, double-blind, placebo-controlled trial, 292 patients 
were enrolled (n = 197 in the ramucirumab arm and n = 95 in the 
placebo arm).7 Patients in REACH and REACH-2 had advanced HCC 
and Barcelona Clinic Liver Cancer stage B or C that was refractory or 
not amenable to locoregional therapy, Child-Pugh A liver disease and 
Eastern Cooperative Oncology Group Performance Status (ECOG 
PS) of 0 or 17,8; REACH-2 had an additional inclusion criterion of 
serum AFP concentration ≥400 ng/mL.7 In both trials, patients were 
randomly assigned (1:1 REACH and 2:1 REACH-2) to receive either 
ramucirumab 8 mg/kg or placebo intravenously for 1 hour every 
2 weeks until disease progression, unacceptable toxicity or with-
drawal of consent.7,8 Patients in REACH and REACH-2 were from 
several geographic regions, including the Americas, Europe, Australia 
and Israel (collectively Region 1); Asia, excluding Japan (Region 2); 
and Japan (Region 3). Both trials complied with the Declaration of 
Helsinki, the International Conference on Harmonisation Guidelines 
for Good Clinical Practice and applicable local regulations. Ethics 
committees at all participating centres approved the protocol, and 
all patients provided written informed consent.
2.2 | Outcomes and assessments
Tumour response was assessed according to RECIST version 1.1.14 
Radiological assessments of tumours were conducted at baseline, 
every 6 weeks during the first 6 months of treatment and every 
9 weeks thereafter. Radiological progression patterns on ramu-
cirumab or placebo in the second-line setting were classified into 
four non-mutually exclusive categories of new extrahepatic le-
sion, new intrahepatic lesion, extrahepatic growth or intrahepatic 
growth based on previously published definitions11 and RECIST 
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Lay Summary
• Development of new extrahepatic lesions in the second-
line setting is associated with worse overall survival and 
post-progression survival in patients with advanced 
hepatocellular carcinoma receiving ramucirumab or 
placebo.
• Patterns of progression may help refine risk characteri-
zation in the design and analysis of second-line and later 
trials.
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data entered into case report forms. The categories were defined 
as follows: new extrahepatic lesion (including new macrovascular 
invasion), patients developed new lesion(s) outside the liver during 
ramucirumab or placebo treatment; new intrahepatic lesion, pa-
tients developed new lesion(s) if the tumour was inside the liver (ie 
hepatic, liver or liver fissure) during ramucirumab or placebo treat-
ment; extrahepatic growth, patients experienced ≥20% growth in 
the target tumour outside the liver during ramucirumab or placebo 
treatment; and intrahepatic growth, patients experienced ≥20% 
growth in the target tumour inside the liver during ramucirumab 
or placebo treatment.11 Overall survival was defined as time from 
randomization to death from any cause. Using radiological lesion 
data captured on the case report form, radiological progression 
patterns on ramucirumab or placebo in REACH and REACH-2 were 
calculated at the time of RECIST progression, with a method con-
sistent with prior studies.11,12 Post-progression survival was de-
fined as time from progression (per RECIST version 1.1) to time 
of death.
2.3 | Statistical analyses
Two hundred thirty-two patients from REACH (n = 151) and 
REACH-2 (n = 81) who did not have a radiological progression pat-
tern during the study were excluded from this analysis (Figure 1). 
Reasons for missing progression pattern included patient who did 
not exhibit progression (ie still receiving benefit of study treat-
ment), death without progression, withdrawal of consent, ≥2 
missed study visits, no documented death or progressive disease, 
patient started a new anticancer therapy, patient was lost to 
follow-up or a patient had no documented post-baseline tumour 
assessments.
All patients included in analyses had at least one radiological 
progression pattern on ramucirumab or placebo in the second-line 
setting, and patients could have ≥1 progression site. Patient data 
were analysed by trial and in a pooled meta-analysis of individ-
ual patient data from REACH and REACH-2. It should be noted 
that for analyses conducted by trial, patients enrolled in REACH 
were included regardless of baseline AFP level, while in the pooled 
analyses, only patients who had AFP concentration ≥400 ng/mL 
were included. Pooling of patient-level data provided a substan-
tially larger patient population, enabling a more precise estimation 
of the treatment effect in subgroup analyses. All pooled efficacy 
analyses were done at the level of individual patient data, strat-
ified by study, as previously described.7 Cox models evaluated 
the effect of progression pattern in the second-line setting on 
OS, adjusting for baseline ECOG PS, AFP concentration, macro-
vascular invasion and study arm. Cox models also evaluated the 
effect of progression pattern in the second-line setting on PPS 




This exploratory analysis included 625 randomized patients with 
advanced HCC who had ≥1 radiological progression pattern on ra-
mucirumab or placebo within the second-line setting (Figure 1). The 
proportion of patients with each progression pattern was similar be-
tween study arms for each trial and the pooled population (Table 1). 
Demographic and disease characteristics by progression pattern 
were generally balanced between treatment arms (Table 2).
3.2 | Overall survival
In an unadjusted Kaplan-Meier analysis, development of new ex-
trahepatic lesions was significantly associated with poorer OS com-
pared to patients who did not develop new extrahepatic lesions 
(5.3 months vs 8.6 months; stratified HR 1.45, 95% CI 1.16-1.82; 
Figure 2).
When adjusting for baseline prognostic factors that were sta-
tistically significant for OS (baseline macrovascular invasion, ECOG 
PS, AFP concentration) and treatment arm, development of new 
F I G U R E  1   Flowchart showing 
derivation of analytic samples for analyses 
in REACH, REACH-2 and the pooled 
population. AFP, alpha-fetoprotein; 
N, number of participants in overall 
population; n, number of participants in 
sample of population; PD, progressive 
disease
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extrahepatic lesions during the study was prognostic for OS in 
REACH [HR 1.84, 95% CI 1.24-2.73, REACH-2 (HR 1.94, 95% CI 
1.05-3.60)] and the pooled population (HR 1.89, 95% CI 1.27-2.83; 
Table 3). No other progression pattern demonstrated a statistically 
significant difference in OS across the study populations (Table 3).
Overall survival by progression pattern on ramucirumab demon-
strated that patients who received ramucirumab had a consistent OS 
benefit compared to those who received placebo in the pooled pop-
ulation: new extrahepatic lesion (HR 0.56, 95% CI 0.39-0.80), new 
intrahepatic lesion (HR 0.70, 95% CI 0.43-1.15), extrahepatic growth 
(HR 0.62, 95% CI 0.43-0.88) and intrahepatic growth (HR 0.68, 95% 
CI 0.48-0.97; Table 4 and Figure 3). Results were similar in REACH 
and REACH-2, although they did not reach statistical significance in 
REACH-2 (Table S1).
3.3 | Post-progression survival
Post-progression survival by radiographic progression patterns was 
examined in 398 patients in REACH, 205 patients in REACH-2 and 
386 patients in the pooled population; 22 patients were excluded 
because of loss to follow-up or withdrawal of consent for follow-
up after progression. After adjusting for prognostic factors at the 
time of radiological progression (ECOG PS and AFP concentration 
at progression), development of new extrahepatic lesions during the 
study was prognostic for PPS in REACH (HR 2.33, 95% CI 1.51-3.60) 
and the pooled population (HR 1.75, 95% CI 1.12-2.74; Table 5), but 
did not reach statistical significance in REACH-2 (HR 1.49, 95% CI 
0.72-3.08; Table 5). No other progression pattern demonstrated a 
statistical difference in PPS across the study populations. Post-
progression survival by progression pattern demonstrated consist-
ent ramucirumab benefit in PPS, irrespective of progression pattern 
(Table S2).
4  | DISCUSSION
This study examined the relationship between radiological pro-
gression patterns during treatment with ramucirumab or placebo 
in the second-line setting and OS and PPS following radiological 
progression. After adjusting for known prognostic factors, devel-
opment of new extrahepatic lesions was prognostic for poorer OS 
and PPS. These findings were consistent in a biomarker-selected 
population of patients (AFP concentration ≥400 ng/mL) with 
advanced HCC, which is notable given the potential for differ-
ent tumour biology and poor prognosis in patients with elevated 
AFP.16,17 These results are supportive of other studies that exam-
ined progression patterns on sorafenib in the first-line setting and 
demonstrated that the development of new extrahepatic lesions, 
compared to other patterns of progression, is associated with poor 
prognosis in patients with advanced HCC.9-11 Compared to other 
radiological progression patterns, the development of new extra-
hepatic lesions on sorafenib was also associated with poor prog-
nosis in second-line trials of regorafenib and tivantinib, regardless 
of treatment.12,13 It is important to note that although patterns 
of progression on sorafenib have been investigated in second-line 
trials of regorafenib12 and tivantinib,13 these studies only identi-
fied the pattern of progression to first-line sorafenib treatment. 
To our knowledge, this is the first study to investigate progression 
patterns in the second-line setting and the potential effect on sec-
ond-line therapy. Thus, more work is needed to confirm whether 
new extrahepatic lesions developed in these second-line settings 
are prognostic of PPS outcomes, as well as whether outcomes are 
similar in biomarker-defined populations. Stratification for pat-
terns of progression has been considered for trial design in HCC in 
a recent consensus manuscript.18
The development of new extrahepatic lesions was associated 
with PPS for patients in REACH and the pooled population, but not 
in REACH-2. We believe this is possibly because of differing patient 
profiles in REACH and REACH-2. One REACH-2 inclusion criterion 
was an AFP ≥400 ng/mL at baseline; this inclusion criterion may indi-
cate that patients enrolled in REACH-2 had differing disease sever-
ity or prognosis from time of enrolment into the clinical trial, which 
could influence the effects that new progression patterns exert on 
outcomes. Additionally, the analytic sample size of REACH-2 was 
smaller than that for REACH and the pooled population. It is possi-
ble that these results did not reach statistical significance given the 
smaller sample size.
TA B L E  1   Radiological progression patterns on ramucirumab or placebo during REACH and REACH-2





















New extrahepatic lesion 81 (42) 72 (33) 48 (35) 24 (33) 85 (38) 72 (41)
New intrahepatic lesion 49 (25) 67 (31) 30 (22) 14 (19) 50 (22) 44 (25)
Extrahepatic growth 66 (34) 76 (35) 61 (44) 32 (44) 89 (40) 68 (39)
Intrahepatic growth 77 (40) 96 (44) 45 (33) 32 (44) 79 (35) 70 (40)
Abbreviations: n, number of patients per category; N, number of patients overall; PL, placebo; RAM, ramucirumab.
aPatients could have had ≥1 pattern of progression. 
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Hepatocellular carcinoma staging and risk assessment, occur-
ring when a patient is diagnosed with advanced HCC, are critical to 
identifying optimal therapy and for disease prognosis.4 However, 
there is a need to identify novel stratification or prognostic factors 
in the design and analysis of later trials to refine risk assessment in 
second-line and later trials. Taken together with prior studies,11-13 
data presented here suggest that radiological progression pat-
terns should continue to be explored as a potential prognostic factor 
and validated in prospective trials.
There are no current data on radiological progression patterns 
and post-progression clinical outcomes for patients with advanced 
HCC who received immunotherapy-based treatments such as bev-
acizumab plus atezolizumab, nivolumab or pembrolizumab,19-24 and 
it is unknown whether associations between progression patterns 
and PPS are similar after treatment with checkpoint inhibitors 
compared to VEGFR-targeted agents. Evidence from studies of 
other solid tumours suggests impending challenges with immune 
checkpoint inhibitors for response assessment.22 For example, 
patients may develop atypical response patterns and/or pseudo-
progression, a phenomenon in which patients initially appear to 
progress but later show a decrease or stabilization in tumour bur-
den.22 Given that several immunotherapies are approved or pend-
ing approval for the treatment of advanced HCC, evaluating the 
impact of progression patterns with these novel therapies will be 
important in assessing whether they will be used in trial design or 
clinical practice.
Some limitations should be considered when interpreting these 
results. Although the data included 2 phase 3 trials and a meta-anal-
ysis of pooled data, which substantially increased the sample size, 
these post hoc analyses were not powered specifically for these 
types of analyses. In this study, we did not know the progression 
patterns of patients on first-line sorafenib or how they may have 
TA B L E  2   Baseline demographic and disease characteristics of pooled patients with alpha-fetoprotein ≥400 ng/mL by radiological 
progression patterns on ramucirumab or placebo
n (%), except 
where indicated

















Sex, male 70 (82) 60 (83) 44 (88) 34 (77) 63 (71) 58 (85) 57 (72) 56 (80)
Age (y), median 62 60 65 62 61 59 63 62
ECOG PS 0 41 (48) 45 (63) 26 (52) 29 (66) 54 (61) 37 (54) 42 (53) 36 (51)
Child-Pugh Score 
A-5
48 (57) 49 (68) 32 (64) 28 (64) 59 (66) 48 (71) 51 (65) 43 (61)
BCLC stage C 77 (91) 70 (97) 38 (76) 35 (80) 87 (98) 65 (96) 64 (81) 55 (79)
Macrovascular 
invasion
28 (33) 26 (36) 18 (36) 10 (23) 27 (30) 18 (27) 34 (43) 27 (39)
Extrahepatic 
spread

























40 (47) 31 (43) 29 (58) 27 (61) 31 (35) 14 (21) 34 (43) 36 (51)
Region 2 (Asia, 
excluding 
Japan)
31 (37) 29 (40) 14 (28) 7 (16) 38 (43) 41 (60) 25 (32) 24 (34)
Region 3 
(Japan)
14 (17) 12 (17) 7 (14) 10 (23) 20 (23) 13 (19) 20 (25) 10 (14)
Aetiology of liver disease
Hepatitis B 
virus
36 (42) 41 (57) 15 (30) 15 (34) 41 (46) 43 (63) 34 (43) 28 (40)
Hepatitis C 
virus
15 (18) 12 (17) 18 (36) 13 (30) 20 (23) 12 (18) 18 (23) 15 (21)
Significant 
alcohol use
19 (22) 9 (13) 11 (22) 7 (16) 19 (21) 7 (10) 14 (18) 15 (21
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; 
EU, Europe; IQR, interquartile range; n, number of patients per category; PL, placebo; RAM, ramucirumab.
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F I G U R E  2   FKaplan-Meier curves of overall survival by radiographic progression patterns. Data presented are combined arms 












































































Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; ECOG PS, Eastern Cooperative 
Oncology Group Performance Status; HR, hazard ratio; PL, placebo; RAM, ramucirumab.
TA B L E  3   Multivariate Cox regression 
analysis of overall survival by radiological 
progression patterns on ramucirumab or 
placebo
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affected progression patterns of patients on ramucirumab or pla-
cebo; however, this was not an aim of these analyses. As reported in 
the Methods, patients who did not have a recorded progression pat-
tern were excluded from analyses. For this reason, these results are 
only generalizable to patients who developed radiological progres-
sion. Since patients in REACH and REACH-2 had only received prior 
sorafenib, which was the only approved first-line treatment when 
these trials were developed,7,8 the potential clinical benefit of ramu-
cirumab after therapies other than sorafenib is also unknown, but 
is currently being investigated as a separate ongoing cohort within 
the REACH-2 study. Additionally, we do not currently have a clear 
understanding of what determines the pattern of progression. More 
work is needed to understand the biological and pathophysiological 
mechanisms contributing to the development of different progres-
sion patterns.
4.1 | Conclusions
Acknowledging the limitations of post-randomization analysis, the 
emergence of new extrahepatic lesions during treatment with ra-
mucirumab or placebo is an independent prognostic factor for OS 
and PPS. The OS benefit of ramucirumab in patients with advanced 
HCC and AFP concentrations ≥400 ng/mL was consistent across all 
radiological progression patterns. The results of these analyses war-
rant further study.
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Yes 157 135 7.6 4.3 0.56 (0.39-0.80)
0.0013
No 241 191 9.4 7.1 0.81 (0.61-1.09)
0.1666
New intrahepatic lesion
Yes 94 72 11.1 4.7 0.70 (0.43-1.15)
0.1579
No 304 254 8.2 5.9 0.72 (0.56-0.93)
0.0115
Extrahepatic growth
Yes 157 132 9.1 5.4 0.62 (0.43-0.88)
0.0076
No 89 70 6.5 4.3 0.54 (0.32-0.91)
0.0213
Intrahepatic growth
Yes 149 127 8.0 5.2 0.68 (0.48-0.97)
0.0347
No 152 123 7.6 5.9 0.99 (0.68-1.44)
0.9657
Abbreviations: CI, confidence interval; HR, hazard ratio; n, number of patients in category; OS, 
overall survival; PL, placebo; RAM, ramucirumab.
TA B L E  4   Subgroup analysis of overall 
survival on ramucirumab or placebo in the 
pooled population
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F I G U R E  3   Kaplan-Meier curves of overall survival by radiographic progression patterns on ramucirumab or placebo during REACH and 



























































Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; ECOG PS, Eastern Cooperative 
Oncology Group Performance Status; HR, hazard ratio; N, number of patients overall.
a22 patients were excluded because of loss to follow-up or withdrawal of consent for follow-up 
after progression. 
TA B L E  5   Multivariate Cox regression 
analysis of post-progression survival by 
radiographic patterns on ramucirumab or 
placebo
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